173 related articles for article (PubMed ID: 11731431)
1. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
[TBL] [Abstract][Full Text] [Related]
2. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
5. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
7. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
9. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
Yoon WH; Jung YJ; Kim TD; Li G; Park BJ; Kim JY; Lee YC; Kim JM; Park JI; Park HD; No ZS; Lim K; Hwang BD; Kim YS
Clin Cancer Res; 2004 Jul; 10(13):4517-26. PubMed ID: 15240544
[TBL] [Abstract][Full Text] [Related]
10. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
Sheu JR; Fu CC; Tsai ML; Chung WJ
Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
[TBL] [Abstract][Full Text] [Related]
11. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo.
Gershenwald JE; Sumner W; Calderone T; Wang Z; Huang S; Bar-Eli M
Oncogene; 2001 Jun; 20(26):3363-75. PubMed ID: 11423987
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
14. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
16. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis.
Reich R; Katz Y; Hadar R; Breuer E
Clin Cancer Res; 2005 May; 11(10):3925-9. PubMed ID: 15897594
[TBL] [Abstract][Full Text] [Related]
17. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
20. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]